

The Role of Secretory IgA and Complement in IgA Nephropathy

Beatrijs D. Oortwijn, PhD,* Jan-Willem Eijgenraam, MD,* Maria-Pia Rastaldi, MD, PhD,†
Anja Roos, PhD,*‡ Mohamed R. Daha, PhD,* and Cees van Kooten, PhD*

Summary: IgA nephropathy (IgAN) is characterized by glomerular deposition of IgA, often together with complement components. This deposited IgA is mainly polymeric in nature. Although early studies suggested a role for local complement activation in the development of glomerular injury in IgAN, recent attention has focused on the involvement of the lectin pathway of complement activation in the progression of renal disease in IgAN. In addition, we have found that glomerular secretory IgA deposition may be one of the initiators of local complement activation in the kidney. In the present review we discuss recent developments in this area and provide a model of how mucosal immunity and renal inflammation may be interconnected.

Semin Nephrol 28:58-65 © 2008 Elsevier Inc. All rights reserved.

Keywords: Secretory IgA, complement activation, IgA nephropathy, mannose binding lectin, antigen-specific IgA

IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. The hallmark of this disease is the deposition of IgA1 in the glomerular mesangium.^{1,2} These deposits are thought to be composed mainly of high-molecular-weight IgA1, sometimes together with IgG or complement components such as C3.³ The disease shows a broad spectrum of clinical presentations, leading to progressive renal failure in a substantial proportion of patients. It has been reported that IgA deposits disappear after transplantation of a kidney from an IgAN patient into a non-IgAN patient.⁴ Furthermore, after renal transplantation recurrent mesangial IgA deposition is observed in about 50% of patients.⁵ These results strongly suggest that the basic

abnormality of the disease lies within the IgA immune system rather than within the kidney. It is likely that several factors contribute to the development of IgAN, including the nature, glycosylation pattern and composition of IgA, dysregulation of the IgA immune response, and changes in the clearance of IgA from the circulation.⁶

Serum levels of IgA are increased in approximately 50% of patients with IgAN.⁷ Importantly, in other diseases associated with increased serum IgA, such as IgA myeloma, mesangial IgA deposition is not seen, suggesting there is something particular about the IgA molecule in IgAN that promotes mesangial deposition. One of the most consistent changes seen in the circulating pool of IgA is aberrant IgA1 glycosylation, possibly owing to a reduced activity of core 1 β 1,3-galactosyltransferase (reviewed by Novak, pp. 78-87). This aberrantly glycosylated IgA also has been shown in glomerular IgA deposits, suggesting such molecules have a predisposition to mesangial deposition compared with normally glycosylated IgA.⁸

The increase in circulating IgA1 levels appears to be the result of an increased production of this isotype by the bone marrow⁹ and a

*Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands.

†Renal Immunopathology Laboratory, San Carlo Borromeo Hospital, Milano, Italy.

‡Department of Clinical Chemistry, Leiden University Medical Center, Leiden, The Netherlands.

Supported by the Dutch Kidney Foundation (C99.1822 to B.D.O., PC95 to A.R.).

Address reprint requests to Cees van Kooten, PhD, Department of Nephrology, Leiden University Medical Center, C3-P, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. E-mail: Kooten@lumc.nl

0270-9295/08/\$ - see front matter

© 2008 Elsevier Inc. All rights reserved. doi:10.1016/j.semnephrol.2007.10.007

low clearance rate by the liver.^{9,10} Mucosal polymeric IgA (pIgA) plasma cell numbers are normal or even reduced in IgAN,¹¹ and pIgA antibody levels in mucosal secretions are not increased and are sometimes lower than controls.¹²

Interestingly, patients with IgAN often present with macroscopic hematuria after upper respiratory tract infections. Mucosal infection or presentation of live microorganisms leads to excess amounts of IgA in the systemic compartment with the propensity to induce glomerular injury. Immunization studies in IgAN, using different antigens and routes of administration, have produced conflicting results with respect to the systemic IgA response.¹²⁻¹⁴ Mucosal and systemic IgA hyporesponsiveness to mucosal immunization with the neoantigen cholera toxin subunit B has been reported.¹² Furthermore, systemic antigen^{12,15,16} challenge results in normal or increased titers of circulating pIgA1 antibodies,^{15,16} with increased levels of IgA in mucosal secretions of IgAN patients.¹⁷

The fundamental result of these changes in the IgA immune system is both a qualitative and quantitative alteration in circulating IgA. We believe these changes have a direct impact on the systemic clearance of IgA and the interaction of systemic IgA with glomerular mesangial cells. These events are the driving force for the local inflammatory response. Based on recent developments, this review primarily focuses on the role of secretory IgA (SIgA) and mannose binding lectin (MBL) in the pathogenesis of IgAN.

IgA

IgA is the most abundantly produced immunoglobulin isotype, and plays a critical role in protecting the host against environmental pathogens at mucosal surfaces.¹⁸ In human beings, IgA in the circulation primarily consists of monomeric IgA, and only 10% to 20% of the IgA is dimeric IgA (dIgA) or pIgA. Furthermore, IgA consists of 2 subclasses, namely IgA1 and IgA2. IgA1 has 10 potential *O*-glycosylation sites and 2 *N*-glycosylation sites. IgA2 has no *O*-glycosylation sites but has 2 to 3 additional *N*-glycosylation sites. In vitro deglycosylation of IgA leads to self-aggregation, suggesting that underglyco-

sylation of IgA may contribute to the generation of high-molecular-weight IgA.¹⁹

In secretions, SIgA is generated during transcytosis of dIgA by epithelial cells, ultimately leading to its association with the extracellular part of the polymeric Ig receptor (secretory component). Besides the presence of SIgA in the mucosa, low levels (10 $\mu\text{g}/\text{mL}$) of SIgA can be detected in serum.^{20,21}

COMPLEMENT IN IgAN

In IgAN, deposits of IgA are associated commonly with the deposition of complement components, most often C3, the membrane attack complex (C5b-9), and properdin.^{22,23} Furthermore, increased levels of split products of activated C3 have been observed in the circulation of patients with IgAN and associated with increased proteinuria and hematuria, suggesting involvement of the alternative pathway in IgAN.²⁴ Indeed, in vitro as well as in vivo studies have shown that pIgA can activate directly the alternative pathway of complement, whereas monomeric IgA is a poor activator of the complement system (Fig. 1).^{25,26} The molecular basis for this difference between monomeric IgA and pIgA is not clear.

Recently, the lectin pathway of complement, with the recognition molecules MBL, H-ficolin,




Figure 1. The 3 complement pathways of complement activation. IgA can activate both the lectin pathway and the alternative pathway. For both pathways, pIgA is a more potent activator than monomeric IgA. MAC, membrane attack complex.

and L-ficolin, was described.^{27,28} MBL is able to bind directly to a number of microorganisms, via carbohydrates expressed on their surface.²⁹ On binding to an activator, MBL activates the complement cascade via the lectin pathway, which plays a critical role in the first line of host defense against these pathogens. Furthermore, genetic polymorphisms in the MBL gene, resulting in low serum MBL levels and nonfunctional MBL, have a negative impact on several chronic diseases.³⁰

Evidence is accumulating that MBL and activation of the lectin pathway of complement also can be unfavorable for disease progression. This has been suggested for rheumatoid arthritis, and also for IgAN, based on renal biopsy studies showing the presence of excess MBL in glomeruli in IgAN.³¹⁻³³ Furthermore, it has been shown that MBL is able to bind pIgA, leading to activation of the lectin pathway in vitro.³⁴ However, there is no difference in the binding of MBL to IgA from healthy subjects or patients with IgAN.³⁵ The carbohydrate recognition domain of MBL is able to bind in a calcium-dependent way to a number of saccharides, such as D-mannose, L-fucose, and *N*-acetylglucosamine. The binding of MBL by IgA is likely to be through the oligomannose structures present in the *N*-linked sugars of the heavy chains of pIgA, however, this requires further confirmation.³⁵

Deposition of MBL in association with IgA, as a marker for lectin pathway activation, has been reported in a subpopulation of IgAN patients,^{31,32,36} but these findings have been questioned by others.³⁷ Furthermore, the relationship of glomerular MBL deposition with parameters of renal damage and complement activation via the lectin pathway is inconsistent between different studies. Recently, our group described a renal biopsy series in which IgA was co-deposited with MBL in 25% of examined patients.³⁸ Furthermore, patients with MBL deposition showed more severe renal disease as compared with MBL-negative cases, suggesting an important role for MBL in disease progression.³⁸ These results indicate that activation of the lectin pathway, initiated via MBL and possibly also L-ficolin, occurs in a subpopulation of IgAN patients, implicating MBL as a biomarker for disease progression in these cases.³⁸ There have

been indications that MBL can be expressed by intrinsic renal cells, but at present the relative contribution of these cells to deposited MBL is unclear. These results indicate that activation of the lectin pathway, initiated via MBL and possibly also L-ficolin, occurs in a subpopulation of IgAN patients, implicating MBL as a biomarker for disease progression in these cases.³⁸

These findings at the biopsy level emphasize the importance of further delineating the precise composition of IgA in mesangial deposits because ultimately these data will inform us about the mechanisms involved in IgA deposition and complement activation in IgAN. Local complement activation will result in cell injury and induction of an inflammatory cascade that contributes to disease progression. The impact of glycosylation has been reviewed in detail elsewhere³⁹ and is not discussed further in this review. We concentrate on recent findings concerning the presence of SIgA in renal deposits.

SIgA IN IgAN

About 40% of patients with IgAN have recurrent episodes of macroscopic hematuria frequently preceded 1 or 1 days earlier by infections. Upper respiratory tract infections occur most frequently,⁴⁰ but occasionally other infections have been implicated, including gastrointestinal and urinary tract infections. Mucosal immunization with a neoantigen in healthy individuals leads not only to a localized mucosal immune response, but also to an antigen-specific immune response in plasma, suggesting a close relationship between the mucosa and bone marrow. This response is reduced after immunization of patients with IgAN.¹²

Production of SIgA is a specific process taking place at mucosal surfaces and occurs after binding of dIgA to the polymeric Ig receptor and transcytosis of this IgA across the mucosal epithelium.⁴¹ Epithelial IgA transport in the opposite direction also has been described, in which SIgA binds selectively to microfold cells irrespective of their antigen-binding specificity, followed by transport of SIgA across the epithelium and targeting to subepithelial dendritic cells (DCs).⁴² In vitro it has been shown that human DCs can bind and endocytose SIgA.⁴³ It has been suggested that this targeting of SIgA to

DCs may play an important role in mucosal immune regulation through modulation of DC activation.⁴²

Importantly, not all retrograde transport seems to be associated directly with DC uptake because small amounts of SIgA also can be found in human serum.^{20,44} Moreover, increased serum levels of SIgA have been reported in various diseases,⁴⁵⁻⁴⁸ indicating that SIgA may be a marker of clinical interest. Recently, our group showed that in purified serum IgA preparations, SIgA is found in high-molecular-weight IgA fractions and that the relative concentration of SIgA is higher in patients with IgAN as compared with controls.³⁵ In serum low concentrations of SIgA were measured but there were no differences in SIgA concentrations between patients with IgAN and healthy subjects. However, there was a correlation between hematuria in patients with IgAN and the serum SIgA concentration.²¹ There also is evidence that systemic clearance of SIgA may be defective in IgAN.⁴⁹

GLYCOSYLATION OF SIgA IN IgAN

As mentioned previously, it has been suggested that the glycosylation of IgA is an important pathogenic factor in IgAN. The predominance of IgA1 in mesangial deposits and the unusual hinge region of IgA1 with multiple O-linked glycosylation sites has stimulated a great deal of interest in changes to IgA1 glycosylation in IgAN. Indeed, both in serum but, more importantly, also in the eluate of isolated glomeruli, a specific reduction of O-linked galactosylation has been observed.⁵⁰⁻⁵² Furthermore, with size fractionation of eluted proteins from kidney sections, it has been found that these deposits contain predominantly high-molecular-weight forms of IgA.⁵³ Recently, we showed a 120-fold accumulation of SIgA, based on a comparison of the composition of serum and glomerular immunoglobulins, in IgA eluted from isolated glomeruli in IgAN.²¹

Previous studies have shown a role for glycosylation of IgA in the binding and activation of mesangial cells.⁵⁴⁻⁵⁷ Stimulation of mesangial cells with high-molecular-weight IgA leads to enhanced production of chemokines and cytokines, including interleukin-6, transforming growth factor- β , tumor necrosis factor- α , monocyte chemoat-

tractant protein-1, interleukin-8, and macrophage inhibitory factor.^{55,58,59} Interestingly, SIgA binds better to mesangial cells than serum IgA, and binding of SIgA results in mesangial cell synthesis and release of increased amounts of interleukin-6.²¹ At present, it is unclear which mesangial cell IgA receptor binds SIgA.

The glycosylation of SIgA is different to serum IgA in several respects. First, SIgA is a tetramolecular complex consisting of 2 IgA molecules, J chain and SC wrapped around the 4 α heavy chains. Modeling of SIgA suggests that the N-glycans of the α heavy chains can be masked by SC.⁶⁰ This also may result in altered exposure of the hinge region O-glycans. Moreover, specific analysis of the glycosylation of the IgA heavy chains present in SIgA has shown different N-glycan structures compared with that of serum IgA. Specifically, terminal N-acetylglucosamine residues are present in the majority of the N-glycans of SIgA.⁶⁰ The O-glycans of the hinge region of the α heavy chain of SIgA1 display a wide range of glycan structures, which for the major part now are characterized.⁶⁰ It would be very interesting to have precise information on the glycosylation of the α heavy chains of SIgA in IgAN, but at present such information is not available.

SIgA IN IgAN BIOPSY SPECIMENS

To confirm the presence of SIgA in glomeruli in IgAN, our group stained kidney biopsy specimens from patients with IgAN for SIgA deposition. In 15% of cases positive staining for mesangial SIgA was observed.⁶¹ In a separate study secretory component deposition was identified in 13 of 191 IgAN renal biopsy specimens, whereas all control biopsy specimens were negative for secretory component.⁶² In a Japanese study all IgAN biopsy specimens studied were positive for secretory component, whereas normal kidneys were negative.⁶³ Interestingly, in this study there was an association between single nucleotide polymorphisms in the polymeric Ig receptor and the presence of IgAN.⁶³ The relationship between secretory component deposition and other molecules in the glomeruli, and clinical parameters of the patients, has not been studied.

In our study, double staining and confocal microscopy showed remarkable colocalization

of SIgA and MBL, supporting the previously reported strong correlation between SIgA and MBL in a subgroup of patients.⁶¹ In addition, there was strong colocalization with C4d, suggesting local complement activation. An association between SIgA and MBL has been reported by other investigators.⁶⁰ Royle et al⁶⁰ suggested that disruption of the noncovalent interactions between secretory component and the IgA heavy chain (ie, at low pH), may lead to MBL binding and subsequent complement activation via the lectin pathway.

The notion of a pathogenic role of SIgA deposition in IgAN and the knowledge that mucosal sites are critical for the generation of SIgA raises interesting questions concerning the involvement of mucosal immune responses in IgAN.

THE ROLE OF THE TONSILS IN IgAN

The tonsils are located at the gateway of the respiratory and alimentary tract and belong to the mucosa-associated lymphoid tissue. The major function of the tonsils is as a first line of defense against viral, bacterial, and food antigens. In IgAN, tonsillar tissue contains more IgA-secreting B cells than healthy subjects and this increase is matched by a parallel increase in the number of dimeric IgA-secreting cells.⁶⁴ Tonsils from patients with IgAN contain more IgA-producing cells compared with controls,⁶⁵ and synthesize IgA1, which is less sialylated than serum IgA1,^{66,67} suggesting that the tonsils may be a source of the IgA that deposits in IgAN.

Stimulation of the tonsils by ultra short wave has been shown to trigger acute changes in the urinary sediment in a subgroup of patients with IgAN but not patients with other renal diseases.⁶⁸ These patients had suffered more frequent episodes of macroscopic hematuria after upper respiratory tract infections and had higher levels of serum SIgA preceding tonsillar stimulation than those IgAN patients who did not respond to tonsillar stimulation.⁶⁸

Although no randomized controlled trials of tonsillectomy in IgAN patients have been reported it has been suggested that tonsillectomy can improve renal outcome in some patients.^{69,70} There is some retrospective evidence from Japan

that tonsillectomy was associated with a favorable effect on long-term renal survival in IgAN patients supporting the notion that the mucosal IgA immune system may have an important role in the pathogenesis of IgAN.⁷¹

IMMUNIZATION STUDIES IN IgAN PATIENTS

Immunization studies examining both systemic and mucosal (oral) secondary immune responses in IgAN have generated conflicting results with respect to serum and mucosal antigen-specific IgA responses.^{15,17,72-75} In IgAN, mucosal immunization with cholera toxin subunit B resulted in an impaired mucosal and systemic antigen-specific IgA response compared with healthy subjects, whereas there was no difference in antigen-specific IgA responses after simultaneous systemic immunization with the neoantigen keyhole limpet hemocyanin.¹²

Recently, Smith et al⁷⁶ described the O-glycosylation pattern of antigen-specific serum IgA1 against the systemic antigen tetanus toxoid and the mucosal antigen *Helicobacter pylori*. In this study higher *Vicia villosa* (a lectin recognizing the Tn-antigen) binding was observed for IgA1 specific for *H pylori* as compared with tetanus toxoid. There were no differences between patients and controls. This suggests that IgA1 O-glycosylation may vary in different immune responses and may be determined at the site of antigen encounter. This also would imply that an altered balance in O-glycosylation pattern of IgA1 in IgAN patients potentially could be a consequence of a mucosal immune response rather than a generic defect in B-cell O-glycosylation.⁷⁶

Recently, we investigated the size distribution of antigen-specific IgA in serum and nasal washes after mucosal and systemic immunization (Eijgenraam et al, unpublished data). Nasal washes contained mainly SIgA whereas serum IgA displayed the usual size distribution of serum IgA, being mainly monomeric. SIgA was detectable in these sera, and, as expected, restricted to the high-molecular-weight IgA fractions. We found that the antigen-specific IgA was found predominantly in the high-molecular-weight fractions, irrespective of the route of administration. Importantly, we also were able to show low but




Figure 2. A model to link mucosal immune responses with deposition of SIgA in the renal mesangium. In IgAN 3 compartments are important: the mucosa, the circulation, and the kidney. B lymphocytes present at mucosal sites will, on activation, produce dIgA which will be secreted predominantly as SIgA across mucosal epithelial surfaces. Via an unknown mechanism, small amounts of SIgA enter the circulation and ultimately come into contact with mesangial cells. At the same time, both mucosal B cells and plasma cells in the bone marrow are producing increasing amounts of aberrantly glycosylated IgA, which enters the circulation. The binding of SIgA and aberrantly glycosylated IgA1 leads to mesangial cell activation. SIgA deposition also is associated with mesangial deposition of MBL and activation of the complement system, resulting in more severe glomerular injury.

significant levels of antigen-specific SIgA in serum after intranasal vaccination, strongly suggesting a link between mucosal immune responses and circulating SIgA (Fig. 2).

CONCLUSIONS

In this review we have discussed the potential role for MBL and SIgA in the pathogenesis of IgAN. pIgA is able to activate the alternative pathway, but also by binding MBL activate the lectin pathway of complement. We also have discussed the mesangial deposition of MBL in IgAN and that this deposition is associated with more severe renal injury.

Patients with IgAN often experience macroscopic hematuria after upper respiratory tract infections. Although there is no obvious increase in serum SIgA in IgAN we have described a clear relationship between serum SIgA concentrations and risk of hematuria in IgAN. Moreover, compared with other serum immunoglobulins SIgA appears to deposit preferentially within glomeruli in IgAN and this is reflected by the SIgA staining observed in kidney biopsy specimens of patients with IgAN. The presence of SIgA is associated strongly with co-deposition of MBL and the complement activation product C4d. Taken together, the data presented in this review support a role for SIgA and MBL in the pathogenesis of IgAN in a sub-population of patients.

REFERENCES

1. Berger J, Hinglais N. Les depots intercapillaires d'IgA-IgG. *J Urol Nephrol* (Paris). 1968;74:694-5.
2. Donadio JV, Grande JP. IgA nephropathy. *N Engl J Med*. 2002;347:738-48.
3. Floege J, Feehally J. IgA nephropathy: recent developments. *J Am Soc Nephrol*. 2000;11:2395-403.
4. Silva FG, Chander P, Pirani CL, et al. Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. *Transplantation*. 1982;33:241-6.
5. Sanfilippo F, Croker BP, Bollinger RR. Fate of four cadaveric donor renal allografts with mesangial IgA deposits. *Transplantation*. 1982;33:370-6.
6. Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy. *Semin Nephrol*. 2004;24:197-217.
7. van der Boog PJ, van Kooten C, de Fijter JW, et al. Role of macromolecular IgA in IgA nephropathy. *Kidney Int*. 2005;67:813-21.
8. Allen AC, Feehally J. IgA1 glycosylation and the pathogenesis of IgA nephropathy. *Am J Kidney Dis*. 2000;35:551-6.
9. van den Wall Bake AW, Daha MR, Haaijman JJ, et al. Elevated production of polymeric and monomeric IgA1 by the bone marrow in IgA nephropathy. *Kidney Int*. 1989;35:1400-4.
10. Harper SJ, Allen AC, Layward L, et al. Increased immunoglobulin A and immunoglobulin A1 cells in bone marrow trephine biopsy specimens in immunoglobulin A nephropathy. *Am J Kidney Dis*. 1994;24:888-92.
11. Harper SJ, Pringle JH, Wicks AC, et al. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. *Kidney Int*. 1994;45:836-44.
12. de Fijter JW, Eijgenraam JW, Braam CA, et al. Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nephropathy. *Kidney Int*. 1996;50:952-61.

13. Brown TA, Clements ML, Murphy BR, et al. Molecular form and subclass distribution of IgA antibodies after immunization with live and inactivated influenza A vaccines. *Adv Exp Med Biol.* 1987; 216B:1691-700.
14. Mascart-Lemone F, Carlsson B, Jalil F, et al. Polymeric and monomeric IgA response in serum and milk after parenteral cholera and oral typhoid vaccination. *Scand J Immunol.* 1988;28:443-8.
15. van den Wall Bake AW, Beyer WE, Evers-Schouten JH, et al. Humoral immune response to influenza vaccination in patients with primary immunoglobulin A nephropathy. An analysis of isotype distribution and size of the influenza-specific antibodies. *J Clin Invest.* 1989;84:1070-5.
16. Layward L, Allen AC, Harper SJ, et al. Increased and prolonged production of specific polymeric IgA after systemic immunization with tetanus toxoid in IgA nephropathy. *Clin Exp Immunol.* 1992;88:394-8.
17. Layward L, Finnemore AM, Allen AC, et al. Systemic and mucosal IgA responses to systemic antigen challenge in IgA nephropathy. *Clin Immunol Immunopathol.* 1993;69:306-13.
18. Kerr MA. The structure and function of human IgA. *Biochem J.* 1990;271:285-96.
19. Kokubo T, Hiki Y, Iwase H, et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. *J Am Soc Nephrol.* 198;9:2048-54.
20. Thompson RA, Asquith P, Cooke WT. Secretory IgA in the serum. *Lancet.* 1969;2:517-9.
21. Oortwijn BD, van der Boog PJ, Roos A, et al. A pathogenic role for secretory IgA in IgA nephropathy. *Kidney Int.* 2006;69:1131-8.
22. Bene MC, Faure GC. Composition of mesangial deposits in IgA nephropathy: complement factors. *Nephron.* 1987;46:219
23. Rauterberg EW, Lieberknecht HM, Wingen AM, et al. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. *Kidney Int.* 1987;31:820-9.
24. Zwirner J, Burg M, Schulze M, et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. *Kidney Int.* 1997;51: 1257-64.
25. Hiemstra PS, Gorter A, Stuurman ME, et al. Activation of the alternative pathway of complement by human serum IgA. *Eur J Immunol.* 1987;17:321-6.
26. Stad RK, Gijlswijk-Janssen DJ, Van Es LA, et al. Complement depletion abolishes IgA-mediated glomerular inflammation in rats. *Exp Nephrol.* 1994;2:182-9.
27. Holmskov U, Thiel S, Jensenius JC. Collections and ficolins: humoral lectins of the innate immune defense. *Annu Rev Immunol.* 2003;21:547-78.
28. Matsushita M, Endo Y, Fujita T. Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. *J Immunol.* 2000;164:2281-4.
29. Neth O, Jack DL, Dodds AW, et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. *Infect Immun.* 2000;68:688-93.
30. Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. *J Clin Invest.* 1999;104:431-7.
31. Endo M, Ohi H, Ohsawa I, et al. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. *Nephrol Dial Transplant.* 1998;13:1984-90.
32. Matsuda M, Shikata K, Wada J, et al. Deposition of mannan binding protein and mannose-binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. *Nephron.* 1998;80: 408-13.
33. Malhotra R, Wormald MR, Rudd PM, et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. *Nat Med.* 1995;1:237-43.
34. Roos A, Bouwman LH, Gijlswijk-Janssen DJ, et al. Human IgA activates the complement system via the mannose-binding lectin pathway. *J Immunol.* 2001;167:2861-8.
35. Oortwijn BD, Roos A, Royle L, et al. Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy. *J Am Soc Nephrol.* 2006;17:3529-39.
36. Hisano S, Matsushita M, Fujita T, et al. Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. *Am J Kidney Dis.* 2001;38:1082-8.
37. Lhotta K, Wurzner R, Konig P. Glomerular deposition of mannose-binding lectin in human glomerulonephritis. *Nephrol Dial Transplant.* 1999;14:881-6.
38. Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. *J Am Soc Nephrol.* 2006;17:1724-34.
39. Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). *Kidney Int.* 2004;65:1544-7.
40. Nicholls KM, Fairley KF, Dowling JP, et al. The clinical course of mesangial IgA associated nephropathy in adults. *QJM.* 1984;53:227-50.
41. Mostov KE. Transepithelial transport of immunoglobulins. *Annu Rev Immunol.* 1994;12:63-84.
42. Cortesy B. Roundtrip ticket for secretory IgA: role in mucosal homeostasis? *J Immunol.* 2007;178:27-32.
43. Heystek HC, Moulon C, Woltman AM, et al. Human immature dendritic cells efficiently bind and take up secretory IgA without the induction of maturation. *J Immunol.* 2002;168:102-7.
44. Delacroix DL, Vaerman JP. A solid phase, direct competition, radioimmunoassay for quantitation of secretory IgA in human serum. *J Immunol Methods.* 1981; 40:345-58.
45. Mole CM, Renoult E, Bene MC, et al. Serum secretory IgA and IgM and free secretory component in IgA nephropathy. *Nephron.* 1995;71:75-8.
46. Rostoker G, Terzidis H, Petit-Phar M, et al. Secretory IgA are elevated in both saliva and serum of patients

- with various types of primary glomerulonephritis. *Clin Exp Immunol.* 1992;90:305-11.
47. Seilles E, Rossel M, Vuitton DA, et al. Serum secretory IgA and secretory component in patients with non-cirrhotic alcoholic liver diseases. *J Hepatol.* 1995;22:278-85.
 48. Yamabe H, Ozawa K, Fukushi K, et al. Elevated serum secretory IgA in patients with IgA nephropathy. *Nephron.* 1989;51:499-501.
 49. Roccatello D, Picciotto G, Coppo R, et al. Clearance of polymeric IgA aggregates in humans. *Am J Kidney Dis.* 1989;14:354-60.
 50. Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. *Kidney Int.* 2001;59:1077-85.
 51. Allen AC, Bailey EM, Brenchley PE, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. *Kidney Int.* 2001;60:969-73.
 52. Tomana M, Matousovic K, Julian BA, et al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. *Kidney Int.* 1997;52:509-16.
 53. Monteiro RC, Halbwegs-Mecarelli L, Roque-Barreira MC, et al. Charge and size of mesangial IgA in IgA nephropathy. *Kidney Int.* 1985;28:666-71.
 54. Novak J, Vu HL, Novak L, et al. Interactions of human mesangial cells with IgA and IgA-containing immune complexes. *Kidney Int.* 2002;62:465-75.
 55. Duque N, Gomez-Guerrero C, Egido J. Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcription factor nuclear factor-kappa B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. *J Immunol.* 1997;159:3474-82.
 56. Fujii K, Muller KD, Clarkson AR, et al. The effect of IgA immune complexes on the proliferation of cultured human mesangial cells. *Am J Kidney Dis.* 1990;16:207-10.
 57. Chen A, Chen WP, Sheu LF, et al. Pathogenesis of IgA nephropathy: in vitro activation of human mesangial cells by IgA immune complex leads to cytokine secretion. *J Pathol.* 1994;173:119-26.
 58. Lai KN, Tang SC, Guh JY, et al. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. *J Am Soc Nephrol.* 2003;14:3127-37.
 59. Gomez-Guerrero C, Lopez-Armada MJ, Gonzalez E, et al. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation. *J Immunol.* 1994;153:5247-55.
 60. Royle L, Roos A, Harvey DJ, et al. Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems. *J Biol Chem.* 2003;278:20140-53.
 61. Oortwijn BD, Rastaldi MP, Roos A, et al. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. *Nephrol Dial Transplant.* 2007;22:3191-5.
 62. Suzuki S, Kobayashi H, Sato H, et al. Immunohistochemical characterization of glomerular IgA deposits in IgA nephropathy. *Clin Nephrol.* 1990;33:66-71.
 63. Obara W, Iida A, Suzuki Y, et al. Association of single-nucleotide polymorphisms in the polymeric immunoglobulin receptor gene with immunoglobulin A nephropathy (IgAN) in Japanese patients. *J Hum Genet.* 2003;48:293-9.
 64. Harper SJ, Allen AC, Pringle JH, et al. Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. *J Clin Pathol.* 1996;49:38-42.
 65. Nagy J, Brandtzaeg P. Tonsillar distribution of IgA and IgG immunocytes and production of IgA subclasses and J chain in tonsillitis vary with the presence or absence of IgA nephropathy. *Scand J Immunol.* 1988;27:393-9.
 66. Itoh A, Iwase H, Takatani T, et al. Tonsillar IgA1 as a possible source of hypoglycosylated IgA1 in the serum of IgA nephropathy patients. *Nephrol Dial Transplant.* 2003;18:1108-14.
 67. Horie A, Hiki Y, Odani H, et al. IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy. *Am J Kidney Dis.* 2003;42:486-96.
 68. Yamabe H, Sugawara T, Nakamura M, et al. Involvement of tonsils in IgA nephropathy. *Acta Otolaryngol Suppl.* 2004;555:54-7.
 69. Akagi H, Kosaka M, Hattori K, et al. Long-term results of tonsillectomy as a treatment for IgA nephropathy. *Acta Otolaryngol Suppl.* 2004;555:38-42.
 70. Bene MC, Faure GC, de Ligny BH, et al. Clinical involvement of the tonsillar immune system in IgA nephropathy. *Acta Otolaryngol Suppl.* 2004;555:10-4.
 71. Xie Y, Nishi S, Ueno M, et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. *Kidney Int.* 2003;63:1861-7.
 72. Waldo FB. Systemic immune response after mucosal immunization in patients with IgA nephropathy. *J Clin Immunol.* 1992;12:21-6.
 73. Leinikki PO, Mustonen J, Pasternack A. Immune response to oral polio vaccine in patients with IgA glomerulonephritis. *Clin Exp Immunol.* 1987;68:33-8.
 74. Endoh M, Suga T, Miura M, et al. In vivo alteration of antibody production in patients with IgA nephropathy. *Clin Exp Immunol.* 1984;57:564-70.
 75. Waldo FB, Cochran AM. Systemic immune response to oral polio immunization in patients with IgA nephropathy. *J Clin Lab Immunol.* 1989;28:109-14.
 76. Smith AC, Molyneux K, Feehally J, et al. O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. *J Am Soc Nephrol.* 2006;17:3520-8.